Verastem | VSTM - Ebitda


Verastem reported $-21.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
AstraZeneca USD 5.23B 272M Sep/2025
Curis USD -12.3M 231K Sep/2023
Cytokinetics USD -277.18M 169.36M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Laboratory Of America USD 588.1M 24.1M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
TG Therapeutics USD 32.69M 5M Sep/2025